Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately:
●(See "Society guideline links: Immune thrombocytopenia (ITP) and other platelet disorders".)
●(See "Society guideline links: von Willebrand disease".)
●(See "Society guideline links: Rare inherited bleeding disorders".)
●(See "Society guideline links: Acquired bleeding disorders".)
International
●European Hematology Association (EHA)-International Society on Thrombosis and Haemostasis (ISTH)-European Association for Haemophilia and Allied Disorders (EAHAD)-European Stroke Organization (ESO): Clinical practice guidance for antithrombotic treatment in patients with hemophilia (2023)
●World Federation of Hemophilia (WFH): Guidelines for the management of hemophilia, 3rd edition (2020)
●ISTH: Recommendations and guidelines on the definition, diagnosis and management of mild hemophilia A (2018)
●ISTH: Recommendations and guidelines on the predictive value of factor VIII/factor IX levels to define the severity of hemophilia (2018)
●ISTH: Recommendations and guidelines on definitions in hemophilia (2014)
Canada
●National Hemophilia Foundation (NHF)-McMaster University: Guideline on care models for haemophilia management (2016)
United States
●National Hemophilia Foundation (NHF): Medical and Scientific Advisory Council (MASAC) recommendations for bleeding prophylaxis in bleeding disorder patients undergoing GI endoscopy (2020)
●NHF: Management of chronic pain in persons with bleeding disorders – Guidance for practical application of the Centers for Disease Control's opioid prescribing guidelines (2020)
●NHF: MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders (2020)
●NHF: Recommendation on the use and management of emicizumab-kxwh (hemlibra) for hemophilia A with and without inhibitors (2020)
●NHF: Guidelines for emergency department management of individuals with hemophilia and other bleeding disorders (2019)
●NHF: MASAC guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A or B (2017)
●NHF-McMaster University: Guideline on care models for haemophilia management (2016)
●NHF: MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding) (2016)
●NHF: MASAC recommendation on SIPPET (Survey of Inhibitors in Plasma-Product-Exposed Toddlers) – Results and recommendations for previously untreated patients with hemophilia (2016)
●NHF: MASAC recommendations on treatment of hepatitis C in individuals with hemophilia and other bleeding disorders (2016)
●NHF: MASAC recommendations regarding doses of clotting factor concentrate in the home (2016)
●NHF: MASAC recommendations regarding girls and women with inherited bleeding disorders (2016)
●NHF: MASAC recommendation on administration of inhibitor bypassing agents in the home for patients with hemophilia and inhibitors (2015)
●NHF: MASAC recommendations on standardized testing and surveillance for inhibitors in patients with hemophilia A and B (2015)
●NHF: MASAC recommendations regarding physical therapy guidelines in patients with bleeding disorders (2015)
●US guidelines for immune tolerance induction in patients with haemophilia A and inhibitors (2015)
●NHF: MASAC recommendation regarding home factor supply for emergency preparedness for patients with hemophilia and other bleeding disorders (2014)
●NHF: MASAC recommendation regarding the use of recombinant clotting factor products with respect to pathogen transmission (2014)
●NHF: MASAC statement regarding use of various clotting factor assays to monitor factor replacement therapy (2014)
●NHF: MASAC recommendations on administration of vaccines to individuals with bleeding disorders (2013)
●NHF: MASAC recommendations on liver biopsy in individuals with hemophilia (2013)
●NHF: MASAC recommendations regarding prophylaxis with bypassing agents in patients with hemophilia and high titer inhibitors (2013)
●NHF: MASAC statement regarding inhibitor risk of factor VIII concentrates (2013)
●NHF: MASAC recommendations regarding inhibitor risk and recombinant factor VIII concentrates (2012)
●NHF: MASAC recommendations regarding standards of service for pharmacy provides of clotting factor concentrates for home use to patients with bleeding disorders (2008)
●NHF: MASAC recommendation regarding the use of bypassing agents in patients with hemophilia A and B or inhibitors (2006)
●NHF: MASAC recommendation regarding factor concentrate prescriptions and formulary development and restrictions (2005)
●NHF: MASAC recommendations on use of COX-2 inhibitors in persons with bleeding disorders (2005)
●NHF: Transition guidelines for people with bleeding disorders (2003)
Europe
●European Hematology Association (EHA)-International Society on Thrombosis and Haemostasis (ISTH)-European Association for Haemophilia and Allied Disorders (EAHAD)-European Stroke Organization (ESO): Clinical practice guidance for antithrombotic treatment in patients with hemophilia (2023)
●European Haemophilia Network (EUHANET): European guidelines for the certification of haemophilia centres (2013)
United Kingdom
●British Society of Haematology (BSH): Guideline on laboratory aspects of assays used in haemostasis and thrombosis (2020)
●BSH: Guideline on the use of prophylactic factor replacement for children and adults with haemophilia A and B (2020)
●United Kingdom Haemophilia Centres Doctors' Organisation (UKHCDO): Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A – Combined analysis of three studies (2019)
●UKHCDO: Recommendations for the clinical interpretation of genetic variants and presentation of results to patients with inherited bleeding disorders (2019)
●UKHCDO: Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving emicizumab (2018)
●UKHCDO and Royal College of Obstetricians & Gynaecologists (RCOG): Green-top guideline on the management of inherited bleeding disorders in pregnancy (2017)
●UKHCDO: Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia (2017)
●UKHCDO: Guidance on the dental management of patients with haemophilia and congenital bleeding disorders (2013, reviewed 2016)
●UKHCDO: Guidance on the use of enhanced half-life coagulation factor concentrates in routine clinical practice (2016)
●UKHCDO: Report on clinical genetic services for haemophilia (2015)
●UKHCDO: Guideline for the diagnosis and management of the rare coagulation disorders (2014)
●UKHCDO: Guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A (2010, reviewed 2014)
●BSH: Guideline for the diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia (2012)
●UKHCDO: Emergency and out of hours care of patients with bleeding disorders – Standards of care for assessment and treatment (2009, reviewed 2013)
●UKHCDO: Guidance on vaccination against hepatitis A and B viruses in patients with inherited coagulation factor deficiencies and von Willebrand disease, update (2013)
●UKHCDO: Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders (2008, reviewed 2013)
●UKHCDO: Practice guidelines for the molecular diagnosis of haemophilia A (2010)
●UKHCDO: Practice guidelines for the molecular diagnosis of haemophilia B (2010)
●UKHCDO: Review with guidelines for the obstetric and gynaecological management of women with inherited bleeding disorders (2006)
India
●Indian Academy of Pediatrics (IAP): Consensus statement on the diagnosis and management of hemophilia (2018)
Australia–New Zealand
●Australian Haemophilia Centre Directors' Organisation (AHCDO): Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy (2019)
●AHCDO and the National Blood Authority (NBA): Guidelines for the management of haemophilia in Australia (2016)
●AHCDO: Guidelines for the management of patients with haemophilia undergoing surgical procedures (2010)
●AHCDO: Guidelines for the treatment of inhibitors in haemophilia A and haemophilia B (2010)
●AHCDO: Guidelines for the management of HIV and hepatitis C infection in people with haemophilia (2008)
●Australian Health Ministers' Advisory Council (AHMAC): Evidence-based clinical practice guidelines for the use of recombinant and plasma-derived FVIII and FIX products (2006)
Japan
●[In Japanese] Japanese Society on Thrombosis and Hemostasis (JSTH): Acquired hemophilia A practice guideline, revised edition (2017)
●[In Japanese] Japanese Society on Thrombosis and Hemostasis (JSTH): Guidelines for hemostasis treatment for hemophilia patients with inhibitors, supplement (2015)
•[In Japanese] JSTH: Guidelines for hemostasis treatment for hemophilia patients with inhibitors, supplement (2014)
•[In Japanese] JSTH: Guidelines for hemostasis treatment for congenital hemophilia patients with inhibitors (revised 2013)
●[In Japanese] JSTH: Guidelines for hemostasis treatment for hemophilia patients without inhibitors, supplement (2015)
•[In Japanese] JSTH: Guidelines for hemostasis treatment for hemophilia patients without inhibitors, supplement (revised 2014)
•[In Japanese] JSTH: Guidelines for hemostasis treatment for hemophilia patients without inhibitors (revised 2013)
